$1.80 -0.05 (-2.70%) Cancer Genetics Inc - NASDAQ

Jan. 18, 2017 | 03:59 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 1.80
Trade Time: Jan 18 03:59 PM Eastern Daylight Time
Change: -0.05 (-2.70%)
Prev Close: 1.85
Open: 1.90
Bid: 1.75
Ask: 1.80
  1. No results found.
  1. Week In Review: JHL Biotech Signs $257 Million Biosimilar Deal With Sanofi

    TalkMarkets | Dec. 10, 2016 | 12:44PM EST
  2. Cancer Genetics to Report Biomarker Findings in Metastatic Clear Cell Renal Carcinoma Using a CGI-Designed NGS Panel

    Benzinga | Nov. 7, 2015 | 20:08PM EST
  3. Cancer Genetics Receives Bankruptcy Court Approval to Purchase Los Angeles-Based Response Genetics, Inc.

    Benzinga | Oct. 2, 2015 | 07:00AM EST
  4. Cancer Genetics, Inc. Increases Access to Proprietary Diagnostics Tests as Part of New Agreement With Blue Cross Blue Shield of Illinois

    Benzinga | Sep. 8, 2015 | 06:32AM EST
  5. Cancer Genetics Inc. Announces a Partnership With ICON's Laboratory Services to Offer Comprehensive Oncology Laboratory Testing and Solutions

    Benzinga | Jul. 7, 2015 | 06:00AM EST
  6. Stock Futures Take A Firm Bounce; Monster, Soufun Set To Rebound

    IBD | Jun. 30, 2015 | 08:08AM EST
  7. Cancer Genetics Selected to Power Next-Generation Sequencing Services for ReproCELL, a Global Regenerative Medicine Market Leader, in a Multi-Year Agreement

    Benzinga | May. 26, 2015 | 06:00AM EST
  8. RedChip Issues Research Update on Cancer Genetics

    Benzinga | May. 18, 2015 | 06:32AM EST
  9. Cancer Genetics, Inc. Receives New York State Licensure for FHACT Cervical Cancer Test

    Benzinga | Apr. 16, 2015 | 06:46AM EST
  10. Cancer Genetics Inc Receives Second Patent For Genomic Cervical Cancer Test; Strengthens Position Of FHACT

    Benzinga | Nov. 11, 2014 | 08:16AM EST
  11. Morning Market Movers

    Benzinga | Nov. 10, 2014 | 09:43AM EST
  12. Morning Market Movers

    Benzinga | Aug. 27, 2014 | 08:39AM EST
  13. Cancer Genetics, Inc. Releases The Only Comprehensive Genomic Test To Diagnose & Stratify The Most Common Form of Leukemia (CLL)

    Benzinga | Aug. 4, 2014 | 06:32AM EST
  14. Cancer Genetics Announces Acquisition Of Gentris Corporation, A Leading Global Pharmacogenomics Company, And Increases Contract Backlog To Over $18 Million

    Benzinga | Jul. 21, 2014 | 06:47AM EST
  15. Cancer Genetics Names John Pappajohn Chairman of the Board of Directors

    Benzinga | Jan. 6, 2014 | 07:01AM EST
Trading Center